Not unlike Afrezza, Lorcaserin too will have strong MD following.

Reason is - both Afrezza and Lorcaserin are better and safer than their competition.

In case on Mannkind, company even provided numerical % of MDs that

will favor Afrezza - I don't remember the exact % but it was the majority.

The one - and IMO - the ONLY reason for Arena not rising higher is

incredibly high short interest number - 45MM. These crooks are fried

but before going BK they will try every HFT trick to keep a lid on it.

And that too, the high SI number, is relevant to MNKD.

It's not an accident that CNBC was mentioning MNKD as 2nd ARNA today while

reporting on Lorcaserin's approval.

E